APA Alıntı

Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018). Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer.

Chicago Stili Alıntı

Boyiadzis, Michael M., John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, ve James L. Gulley. "Significance and Implications of FDA Approval of Pembrolizumab for Biomarker-defined Disease." J Immunother Cancer 2018.

MLA Alıntı

Boyiadzis, Michael M., et al. "Significance and Implications of FDA Approval of Pembrolizumab for Biomarker-defined Disease." J Immunother Cancer 2018.